Comparative Pharmacology
Head-to-head clinical analysis: PURIXAN versus TREXALL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PURIXAN versus TREXALL.
PURIXAN vs TREXALL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purixan (mercaptopurine) is a purine analog that inhibits de novo purine synthesis by interfering with nucleotide interconversion and incorporation into DNA and RNA. It requires intracellular activation to 6-mercaptopurine ribonucleotide (6-MP ribonucleotide) via hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
Methotrexate is a folate analog that inhibits dihydrofolate reductase, preventing the conversion of folic acid to tetrahydrofolate, thereby inhibiting DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and release of adenosine.
75 mg/kg once weekly orally; may be increased by 25 mg/kg every 2-4 weeks to a maximum of 150 mg/kg once weekly.
Oral: 7.5-15 mg once weekly; subcutaneous: 7.5-15 mg once weekly for rheumatoid arthritis; may be increased up to 25-30 mg weekly based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment. Clinically, monitoring for myelosuppression is essential due to accumulation.
Terminal elimination half-life is 3-10 hours; for high-dose methotrexate, half-life is 8-15 hours. Clinically, monitoring at 24, 48, and 72 hours is standard to guide leucovorin rescue
Renal excretion of unchanged drug and metabolites; approximately 50% as unchanged drug, 20% as 6-thiouric acid, and minor amounts as other metabolites. Biliary/fecal elimination accounts for less than 10%.
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal elimination is minor (<10%)
Category C
Category C
Antimetabolite
Antimetabolite